AI Adoption Is Accelerating, But Where Is the Oversight?
A governance workshop to keep your data safe.
Your commercial and medical affairs teams are already using AI assistants every day. Does your legal and compliance team know which ones, or what those tools touch? Join CI's Claudia Beqaj and Classie AI co-founder Dr. Lawrence Spracklen for a live conversation on the real risks life sciences companies face right now: PHI exposure, rare disease de-identification, and audit trails that hold up under scrutiny.
Webinar Starts In
Real controls for real agents, not just a policy document
A governance workshop to keep your data safe. This session covers where AI oversight is falling behind in life sciences today, with real answers on PHI, rare disease data, and proof that holds up under audit.
Whether your commercial and medical affairs teams using AI tools is a data risk or a compliance risk
What "your data never leaves our environment" actually means in practice
How rare disease programs handle re-identification risk at small patient counts
How to build an audit trail that holds up under regulatory scrutiny
Gradial
PEGA